[Form 4] Cumberland Pharmaceuticals Inc Insider Trading Activity

Rhea-AI Filing Summary

Caroline Young, a director of Cumberland Pharmaceuticals Inc. (CPIX), purchased shares of the company in multiple automatic trades executed during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. The reported purchases occurred across trading dates from July 1 through July 31, 2025, at per-share prices ranging about $3.05 to $3.82. Following the reported transactions, her beneficial ownership increased from 32,661 shares to 32,821 shares, a net gain of 160 shares.

The filing confirms the trades were made pursuant to the pre-established 10b5-1 plan and signed by an attorney-in-fact on behalf of the reporting person. No sales, derivative transactions, or other changes in relationship to the issuer are reported in this Form 4.

Positive

• Insider purchases executed under a Rule 10b5-1 plan, providing an affirmative-defense framework for the trades.
• Beneficial ownership increased by 160 shares, from 32,661 to 32,821 shares, all acquired in July 2025.
• Purchase prices disclosed for each trade, ranging approximately between $3.05 and $3.82 per share, improving transparency.

Negative

• None.

Insights

Securities Analyst

TL;DR: Director purchases were routine automatic executions under a 10b5-1 plan, resulting in a small increase in beneficial ownership to 32,821 shares.

The Form 4 documents a sequence of small, daily purchases in July 2025 executed under a Rule 10b5-1 plan adopted November 14, 2024. Transaction prices reported range roughly from $3.05 to $3.82 per share. The incremental increase of 160 shares is immaterial to market capitalization but is a clear, documented instance of insider buying under an affirmative-defense trading plan. There are no reported dispositions or derivative positions disclosed.

Corporate Governance Expert

TL;DR: The filing reflects standard governance-compliant insider trading via a certified 10b5-1 plan with attorney-in-fact signature, showing orderly purchases only.

The report states the purchases were automatic pursuant to a Rule 10b5-1 plan, which provides an affirmative defense to insider trading allegations when properly adopted. The signature by an attorney-in-fact is documented. The pattern shows multiple small acquisitions over one month with no accompanying disclosures of sales or option exercises, consistent with plan-driven executions rather than ad hoc trading.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Caroline

(Last) (First) (Middle)

1600 WEST END AVENUE

SUITE 1300

(Street)

NASHVILLE TN 37203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		P	V	8(1)	A	$3.56	32,661	D
Common Stock	07/02/2025		P	V	8(1)	A	$3.52	32,669	D
Common Stock	07/03/2025		P	V	8(1)	A	$3.531	32,677	D
Common Stock	07/07/2025		P	V	8(1)	A	$3.23	32,685	D
Common Stock	07/08/2025		P	V	8(1)	A	$3.06	32,693	D
Common Stock	07/09/2025		P	V	8(1)	A	$3.05	32,701	D
Common Stock	07/10/2025		P	V	8(1)	A	$3.2	32,709	D
Common Stock	07/11/2025		P	V	8(1)	A	$3.21	32,717	D
Common Stock	07/14/2025		P	V	8(1)	A	$3.46	32,725	D
Common Stock	07/15/2025		P	V	8(1)	A	$3.45	32,733	D
Common Stock	07/16/2025		P	V	8(1)	A	$3.79	32,741	D
Common Stock	07/17/2025		P	V	8(1)	A	$3.82	32,749	D
Common Stock	07/18/2025		P	V	8(1)	A	$3.59	32,757	D
Common Stock	07/21/2025		P	V	8(1)	A	$3.45	32,765	D
Common Stock	07/22/2025		P	V	8(1)	A	$3.47	32,773	D
Common Stock	07/23/2025		P	V	8(1)	A	$3.54	32,781	D
Common Stock	07/24/2025		P	V	8(1)	A	$3.55	32,789	D
Common Stock	07/25/2025		P	V	8(1)	A	$3.37	32,797	D
Common Stock	07/28/2025		P	V	6(1)	A	$3.47	32,803	D
Common Stock	07/29/2025		P	V	6(1)	A	$3.33	32,809	D
Common Stock	07/30/2025		P	V	6(1)	A	$3.55	32,815	D
Common Stock	07/31/2025		P	V	6(1)	A	$3.5	32,821	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	Caroline Young by /s/ John Hamm as attorney-in-fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Caroline Young report on the CPIX Form 4?

The Form 4 reports multiple purchases of Cumberland Pharmaceuticals (CPIX) common stock in July 2025 executed under a Rule 10b5-1 trading plan.

How many shares did Caroline Young own after the reported transactions?

Following the reported July 2025 trades, her beneficial ownership is reported as 32,821 shares.

Over what dates did the reported insider purchases occur?

The disclosed purchases occurred on trading dates from July 1, 2025 through July 31, 2025.

What price range was paid for the CPIX shares in these transactions?

The reported per-share prices range approximately from $3.05 to $3.82 across the July trades.

Were the purchases part of a 10b5-1 plan and when was it adopted?

Yes. The filing states the purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.